Montelukast is a medicine widely used to prevent and treat asthma, a condition that makes breathing difficult due to inflammation and narrowing of the airways in the lungs. Asthma can be caused by genetics, environmental factors, or a combination of both, and it often involves allergies. Common allergens triggering asthma include dust mites, pet dander, pollens, molds, and various irritants. Symptoms of asthma include wheezing, coughing, difficulty breathing, and a tight chest feeling. In the United States, around 27 million people have asthma, with one in every 12 children affected. Different types of asthma exist, such as allergic, non-allergic, late-onset, fixed airflow limitation, and obesity-related asthma.
The demand for asthma treatment is rising due to increasing cases, deaths, pollution, a growing elderly population, and increased awareness of early asthma diagnosis. In 2016, there were 420,000 asthma-related deaths globally, according to the Global Burden of Disease research. Montelukast belongs to a group of medicines called leukotriene receptor antagonists, helping reduce inflammation and nasal congestion to keep airways open. It is also used for treating allergic rhinitis (hay fever) caused by allergens like pollen, dust, mold, or animal skin flakes. Around 8% of adults in the US experience allergic rhinitis. Additionally, montelukast is used to prevent breathing difficulties during exercise. With the increasing incidence of asthma and growing health awareness, the demand for montelukast is expected to rise, driving the global market growth.
Montelukast, widely used for asthma prevention and treatment, plays a crucial role in alleviating breathing difficulties caused by inflammation in the airways. It addresses asthma triggered by various factors, including genetics, environmental elements, and allergies to substances like dust, pet dander, pollen, and mold. The medicine is vital in managing symptoms such as wheezing, coughing, and chest tightness associated with asthma. With approximately 27 million Americans affected by asthma, including one in every 12 children, the demand for effective asthma treatment is on the rise. Montelukast belongs to the leukotriene receptor antagonist family, known for reducing inflammation and nasal congestion to maintain open airways. Additionally, it aids in treating allergic rhinitis caused by allergens and preventing breathing issues during exercise. As awareness about asthma increases and its global prevalence continues, montelukast is anticipated to play a significant role in meeting the growing demand for effective respiratory care.
Covered Aspects:Report Attribute/Metric | Details |
---|---|
Market Opportunities | Opportunities associated with the technological advancements |
Market Dynamics | Increasing prevalence of diseases like asthma, allergic rhinitis, etc. |
ยฉ 2025 Market Research Future ยฎ (Part of WantStats Reasearch And Media Pvt. Ltd.)